Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A PROSPECTIVE RANDOMIZED TRIAL COMPARING SOMATOSTATIN AND SCLEROTHERAPY IN THE TREATMENT OF ACUTE VARICEAL BLEEDING
Autore:
PLANAS R; QUER JC; BOIX J; CANET J; ARMENGOL M; CABRE E; PINTANEL T; HUMBERT P; OLLER B; BROGGI MA; GASSULL MA;
Indirizzi:
HOSP UNIV GERMANS TRIAS & PUJOL,DEPT GASTROENTEROL,CARRETERA CANYET S-N E-08916 BARCELONA SPAIN HOSP UNIV GERMANS TRIAS & PUJOL,DEPT ANESTHESIOL E-08916 BARCELONA SPAIN HOSP UNIV GERMANS TRIAS & PUJOL,DEPT SURG E-08916 BARCELONA SPAIN
Titolo Testata:
Hepatology
fascicolo: 2, volume: 20, anno: 1994,
pagine: 370 - 375
SICI:
0270-9139(1994)20:2<370:APRTCS>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
ESOPHAGEAL-VARICES; BALLOON TAMPONADE; ENDOSCOPIC SCLEROTHERAPY; SPLANCHNIC HEMODYNAMICS; INJECTION SCLEROTHERAPY; EMERGENCY SCLEROTHERAPY; ACUTE HEMORRHAGE; DOUBLE-BLIND; VASOPRESSIN; COMPLICATIONS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
36
Recensione:
Indirizzi per estratti:
Citazione:
R. Planas et al., "A PROSPECTIVE RANDOMIZED TRIAL COMPARING SOMATOSTATIN AND SCLEROTHERAPY IN THE TREATMENT OF ACUTE VARICEAL BLEEDING", Hepatology, 20(2), 1994, pp. 370-375

Abstract

Somatostatin and endoscopic sclerotherapy are widely used in the treatment of acute variceal bleeding. Although objective evidence does exist about the advantages of either treatment, data comparing both procedures are scarce. In order to compare the effectiveness and safety of somatostatin and sclerotherapy in the treatment of acute variceal bleeding, 70 consecutive cirrhotic patients suffering from esophageal variceal hemorrhage and meeting the inclusion criteria were randomly assigned to treatment with somatostatin (35 patients) or sclerotherapy (35 patients). No differences in age, sex, alcohol intake, etiology of cirrhosis and severity of liver failure were found between groups. Failure of treatment (defined as persistence of bleeding despite therapy or subsequent rebleeding within the 48-hr trial period) occurred in sevenpatients (20%) in the somatostatin group and in six (17.1%) in the sclerotherapy group (NS). Early rebleeding occurred in seven of 28 patients (25%) in the somatostatin group and in five of 29 (17.2%) in the sclerotherapy group (NS). Mortality within the first 6 wk was no different between both groups: 10 (28.5%) and eight (22.8%) in the somatostatin and sclerotherapy groups, respectively. Sclerotherapy, but not somatostatin, was associated with major complications in five cases (14.2%) (p = 0.026), two of which resulted in patient's death. These results suggest that somatostatin is safer, and as effective as sclerotherapy, in controlling acute variceal bleeding until an elective treatment can be established.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 10:17:01